UNSPSC 51312108: Olopatadine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H23NO3.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2XG66W44KF, chemically known as 11-((z)-3-(dimethylamino)propylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid but more generally known as olopatadine hydrochloride, which bears US NIH Compound Identifier 5281071. European Medicines Agency schedules Olopatadine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03509MIG.

UNSPSC 51312108 Olopatadine hydrochloride, a Commodity code, shows minimal alignment between the code's nominal scope—a specific ophthalmic antihistamine—and the actual state and local procurement activity posted under it. Recent solicitations tagged to this code involve naloxone kits, drug deactivation systems, and broad pharmaceutical procurement programs, none of which involve olopatadine. The code does not support active market demand for the product named; state and local buyers posting opportunities under this classification are pursuing emergency medical supplies, pharmacy benefit administration, and multi-source generic drug distribution through cooperative purchasing vehicles rather than procurement of a single branded or generic antihistamine ingredient.

Geographic activity spans Florida, Texas, and Minnesota through recent postings. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: deadline date precedes posting date in source, indicating data quality issues). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026. The MMCAP opportunity spans participating state and local government facilities across multiple states. The fundamental mismatch between the code name and the work being procured suggests either systematic miscoding or limited procurement volume under the actual olopatadine product line.